All news

Vaxcyte Bolsters Capital Structure with New Offerings

Alpha Vantage · The Globe and Mail · · AI-summarised by FinFlash

Vaxcyte (PCVX) closed concurrent equity and convertible debt offerings, raising about $544.3 million from equity and $558.7 million from debt. The deals included $575 million in convertible senior notes plus common stock and pre-funded warrants, giving the biotechnology company greater financial flexibility for strategic and operational initiatives.

Read original source

PCVX company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.